Search Result

Results for "

FUTs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (1) Akt (1) Apoptosis (3) Autophagy (1) Biochemical Assay Reagents (1) C-type Lectin-like Receptors (CTLRs) (1) CCR (4) CD19 (1) CD20 (1) CD276/B7-H3 (1) Drug Intermediate (1) EGFR (5) Endogenous Metabolite (1) FGFR (1) Flavivirus (2) Gap Junction Protein (1) Glucosylceramide Synthase (GCS) (3) Glycosyltransferase (3) Human leukocyte immunoglobulin (Ig)-like receptors (LILR) (1) iGluR (4) Interleukin Related (1) mTOR (1) NF-κB (3) Orexin Receptor (OX Receptor) (1) Reference Standards (2) Ser/Thr Protease (2) Small Interfering RNA (siRNA) (25) TNF Receptor (4) Transmembrane Glycoprotein (3)
By Research Areas:	Cancer (25) Infection (3) Inflammation/Immunology (8) Metabolic Disease (1) Neurological Disease (4)
Oligonucleotides:	Rat Pre-designed siRNA Sets (7) Mouse Pre-designed siRNA Sets (7) Human Pre-designed siRNA Sets (11) siRNAs (25)

Inhibitors & Agonists

Biochemical Assay Reagents

Inhibitory Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0190A

Nafamostat mesylate Maximum Cited Publications 18 Publications Verification FUT-175	Flavivirus TNF Receptor NF-κB Apoptosis Ser/Thr Protease	Infection Cancer
Nafamostat mesylate (FUT-175), an anticoagulant, is a synthetic serine protease inhibitor. Nafamostat mesylate has anticancer and antivirus effect. Nafamostat mesylate induce apoptosis by up-regulating the expression of tumor necrosis factor receptor-1 (TNFR1). Nafamostat mesylate can be used in the development of the pathological thickening of the arterial wall .

HY-W096600

2F-Peracetyl-Fucose 3 Publications Verification 1,3,4-Tri-O-acetyl-2-deoxy-2-fluoro-L-fucopyranos	Glycosyltransferase	Cancer
2F-Peracetyl-Fucose (1,3,4-Tri-O-acetyl-2-deoxy-2-fluoro-L-fucopyranos) acts as a potent fucosyltransferase (FUT) inhibitor .

HY-155747

FDW028 1 Publications Verification	Autophagy Akt mTOR	Cancer
FDW028 a potent and highly selective FUT8 inhibitor. FUT8 exhibits potent anti-tumor activity by defucosylation and impelling lysosomal degradation of B7-H3 through the chaperone-mediated autophagy (CMA) pathway. FDW028 can be used for metastatic colorectal cancer (mCRC) research .

HY-P99113A

*Inebilizumab (FUT8-KO)*	CD19	Inflammation/Immunology
Inebilizumab (FUT8-KO) is an anti-CD19 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody.Inebilizumab (FUT8-KO) exhibits enhanced ADCC against B cells and can be used for research on multiple sclerosis and neuromyelitis optica .

HY-P99010A

*Bemarituzumab (FUT8-KO)*	Interleukin Related FGFR	Cancer
Bemarituzumab (FUT8-KO) is an anti-FGFR2b monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Bemarituzumab (FUT8-KO) lacks a core fucose in the polysaccharide portion of the Fc domain of the antibody, and results in a high affinity to human FcγRIIIa .

HY-P99406A

*Petosemtamab (FUT8-KO)*	EGFR	Cancer
Petosemtamab (FUT8-KO) is an anti-EGFR and anti-LGR5 monoclonal antibody expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucosyl loss enhances the ADCC effect of the antibody. Petosemtamab (FUT8-KO) leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab (FUT8-KO) can be used for research on solid tumors such as head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC) .

HY-P99653A

*Ianalumab (FUT8-KO)* VAY-736 (FUT8-KO)	TNF Receptor Apoptosis NF-κB	Inflammation/Immunology Cancer
Ianalumab (VAY-736) (FUT8-KO) is an anti-BAFF-R monoclonal antibody expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose depletion enhances its B cell clearance capacity. Ianalumab (FUT8-KO) competitively blocks the binding of BAFF to BAFF-R, inhibits the BAFF-mediated alternative NF-κB pro-survival signaling pathway, and abrogates the apoptotic (apoptosis) protective effect of BAFF on cancer cells. Ianalumab (FUT8-KO) can be used in research related to primary Sjögren's syndrome and chronic lymphocytic leukemia .

HY-P9977A

*Amivantamab (FUT8-KO)*	EGFR	Cancer
Amivantamab (FUT8-KO) is an anti-EGFR-MET monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Amivantamab (FUT8-KO) inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .

HY-136299

Sepimostat 2 Publications Verification FUT-187 free base	iGluR	Neurological Disease
Sepimostat (FUT-187 free base) exhibits neuroprotective activity via NR2B N-methyl-D-aspartate receptor antagonism at the Ifenprodil-binding site of the NR2B subunit. Sepimostat inhibits the Ifenprodil binding with a K_i value of 27.7?μM .

HY-P9980A

*Belantamab (FUT8-KO)*	ADC Antibody TNF Receptor	Cancer
Belantamab (FUT8-KO) is an anti-BCMA (TNFRSF17) monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Belantamab (FUT8-KO) can be used to synthesize antibody-active molecule conjugate (ADC), Belantamab mafodotin .

HY-E70157

Fucosyltransferase 8 1 Publications Verification EC:2.4.1.68; FUT8; α1-6FucT	Glucosylceramide Synthase (GCS)	Infection
Fucosyltransferase 8 (EC:2.4.1.68; FUT8; α1-6FucT) is a glycosyl transferase and catalyzes the transfer of a fucose residue from GDP-fucose to the innermost N-acetylglucosamine residue of N-glycans .

HY-P99295A

*Imgatuzumab (FUT8-KO)* RG 7160 (FUT8-KO); RO 5083945 (FUT8-KO); Anti-EGFR Recombinant Antibody (FUT8-KO)	EGFR	Cancer
Imgatuzumab (FUT8-KO) is a humanized monoclonal antibody against EGFR expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Imgatuzumab is an immunomodulator. Imgatuzumab may be used in cancer research.

HY-RS05153

FUT2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FUT2 Human Pre-designed siRNA Set A contains three designed siRNAs for FUT2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FUT2 Human Pre-designed siRNA Set A FUT2 Human Pre-designed siRNA Set A

HY-RS05159

FUT8 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FUT8 Human Pre-designed siRNA Set A contains three designed siRNAs for FUT8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FUT8 Human Pre-designed siRNA Set A FUT8 Human Pre-designed siRNA Set A

HY-B0190AR

Nafamostat mesylate (Standard) FUT-175 (Standard)	Flavivirus TNF Receptor NF-κB Apoptosis Ser/Thr Protease Reference Standards	Infection Cancer
Nafamostat (mesylate) (Standard) is the analytical standard of Nafamostat (mesylate). This product is intended for research and analytical applications. Nafamostat mesylate (FUT-175), an anticoagulant, is a synthetic serine protease inhibitor. Nafamostat mesylate has anticancer and antivirus effect. Nafamostat mesylate induce apoptosis by up-regulating the expression of tumor necrosis factor receptor-1 (TNFR1). Nafamostat mesylate can be used in the development of the pathological thickening of the arterial wall .

HY-170541

FUT8-IN-1	Glucosylceramide Synthase (GCS)	Inflammation/Immunology
FUT8-IN-1 (Compound 37) is an inhibitor for α-1,6-fucosyltransferase (FUT8) with an K_D of 49 nM and an IC₅₀ of ca. 50 µM. FUT8-IN-1 generates a highly active naphthoquinone imine intermediate in the presence of *FUT8, and inhibits the enzymatic activity of FUT8* .

HY-136299A

Sepimostat dimethanesulfonate FUT-187	iGluR	Neurological Disease
Sepimostat dimethanesulfonate (FUT-187) exhibits neuroprotective activity via NR2B N-methyl-D-aspartate receptor antagonism at the Ifenprodil-binding site of the NR2B subunit. Sepimostat dimethanesulfonate inhibits the Ifenprodil binding with a K_i value of 27.7 µM .

HY-E70154

Fucosyltransferase 3 EC:2.4.1.65; FUT3; FT3B	Glycosyltransferase	Others
Fucosyltransferase 3 (EC:2.4.1.65, FUT3, FT3B) has strong alpha 1-3 and alpha 1-4 fucosyltransferase activities .

HY-E70159

Fucosyltransferase 11 EC:2.4.1.-; FUT11	Glycosyltransferase	Cancer
Fucosyltransferase 11 (EC:2.4.1.-, FUT11) links alpha-l-fucose onto conalbumin glycopeptides and biantennary N-glycan acceptors. Fucosyltransferase 11 plays an important role in cancer .

HY-E70156

Fucosyltransferase 7 EC:2.4.1.-; FUT7	Biochemical Assay Reagents	Others
Fucosyltransferase 7 (FUT7) is a golgi stack membrane protein. Fucosyltransferase 7catalyzes the final fucosylation step in the synthesis of Lewis antigens and generates a unique glycosylated product sialyl Lewis X (sLeX). Fucosyltransferase 7 catalyzes alpha-1,3 glycosidic linkages involved in the expression of sialyl Lewis X antigens .

HY-RS29041

Fut11 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Fut11 Rat Pre-designed siRNA Set A contains three designed siRNAs for Fut11 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Fut11 Rat Pre-designed siRNA Set A Fut11 Rat Pre-designed siRNA Set A

HY-RS05157

FUT6 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FUT6 Human Pre-designed siRNA Set A contains three designed siRNAs for FUT6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FUT6 Human Pre-designed siRNA Set A FUT6 Human Pre-designed siRNA Set A

HY-RS05158

FUT7 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FUT7 Human Pre-designed siRNA Set A contains three designed siRNAs for FUT7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FUT7 Human Pre-designed siRNA Set A FUT7 Human Pre-designed siRNA Set A

HY-RS05154

FUT3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FUT3 Human Pre-designed siRNA Set A contains three designed siRNAs for FUT3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FUT3 Human Pre-designed siRNA Set A FUT3 Human Pre-designed siRNA Set A

HY-RS05156

FUT5 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FUT5 Human Pre-designed siRNA Set A contains three designed siRNAs for FUT5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FUT5 Human Pre-designed siRNA Set A FUT5 Human Pre-designed siRNA Set A

HY-RS05160

FUT9 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FUT9 Human Pre-designed siRNA Set A contains three designed siRNAs for FUT9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FUT9 Human Pre-designed siRNA Set A FUT9 Human Pre-designed siRNA Set A

HY-RS18933

Fut7 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Fut7 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Fut7 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Fut7 Mouse Pre-designed siRNA Set A Fut7 Mouse Pre-designed siRNA Set A

HY-RS05150

FUT1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FUT1 Human Pre-designed siRNA Set A contains three designed siRNAs for FUT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FUT1 Human Pre-designed siRNA Set A FUT1 Human Pre-designed siRNA Set A

HY-RS22520

Fut11 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Fut11 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Fut11 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Fut11 Mouse Pre-designed siRNA Set A Fut11 Mouse Pre-designed siRNA Set A

HY-RS22175

Fut9 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Fut9 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Fut9 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Fut9 Mouse Pre-designed siRNA Set A Fut9 Mouse Pre-designed siRNA Set A

HY-RS05152

FUT11 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FUT11 Human Pre-designed siRNA Set A contains three designed siRNAs for FUT11 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FUT11 Human Pre-designed siRNA Set A FUT11 Human Pre-designed siRNA Set A

HY-RS05155

FUT4 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FUT4 Human Pre-designed siRNA Set A contains three designed siRNAs for FUT4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FUT4 Human Pre-designed siRNA Set A FUT4 Human Pre-designed siRNA Set A

HY-RS25423

Fut7 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Fut7 Rat Pre-designed siRNA Set A contains three designed siRNAs for Fut7 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Fut7 Rat Pre-designed siRNA Set A Fut7 Rat Pre-designed siRNA Set A

HY-P9991A

*Osemitamab (FUT8-KO)*	Gap Junction Protein	Cancer
Osemitamab (FUT8-KO) is an anti-claudin-18.2 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .

HY-136299R

Sepimostat (Standard) FUT-187 free base (Standard)	iGluR Reference Standards	Neurological Disease
Sepimostat (Standard) is the analytical standard of Sepimostat. This product is intended for research and analytical applications. Sepimostat (FUT-187 free base) exhibits neuroprotective activity via NR2B N-methyl-D-aspartate receptor antagonism at the Ifenprodil-binding site of the NR2B subunit. Sepimostat inhibits the Ifenprodil binding with a Ki value of 27.7 μM .

HY-E70158

Fucosyltransferase 9 EC:2.4.1.152; FUT9	Drug Intermediate	Others
Fucosyltransferase 9 (EC:2.4.1.152, FUT9) catalyzes the last step in the biosynthesis of Lewis antigen, the addition of a fucose to precursor polysaccharides. Fucosyltransferase 9 synthesizes the LeX oligosaccharide (CD15) .

HY-P990026A

*Ulviprubart (FUT8-KO)*	C-type Lectin-like Receptors (CTLRs)	Inflammation/Immunology
Ulviprubart (FUT8-KO) is a humanized anti-KLRG1 monoclonal antibody lacking fucosyltransferase 8 (FUT8). Ulviprubart (FUT8-KO) can be used for the research of diseases such as inclusion body myositis (IBM) .

HY-P991892A

*IT1208 (FUT8-KO)*	Transmembrane Glycoprotein	Cancer
IT1208 (FUT8-KO) is a humanized anti-CD4 monoclonal IgG1 antibody that has knocked out the fucosyltransferase 8 gene (FUT8). It exhibits enhanced antibody-mediated cytotoxicity (ADCC) effect. IT1208 (FUT8-KO) can effectively eliminate CD4+ T cells in vivo and shows controllable safety. IT1208 (FUT8-KO) can be used in related research on colon cancer .

HY-P991092A

*IBI-334 (FUT8-KO)*	EGFR CD276/B7-H3	Cancer
IBI-334 (FUT8-KO) is a bispecific B7-H3 and EGFR antibody that has knocked out the fucosyltransferase 8 gene (FUT8). IBI-334 (FUT8-KO) has an EGFR arm for signal blocking and is coupled with a fine-tuned B7-H3 arm with the best affinity and binding domain. IBI-334 (FUT8-KO), compared to IBI-334 (HY-P991092), has enhanced antibody-mediated cytotoxicity (ADCC) effect. IBI-334 (FUT8-KO) has wide applications in many EGFR-driven solid tumors .

HY-P992005A

*DS-1055a (FUT8-KO)*	Transmembrane Glycoprotein	Cancer
DS-1055a (FUT8-KO) is an anti-human GARP antibody that has knocked out the fucosyltransferase 8 gene (FUT8). It exhibits enhanced antibody-mediated cytotoxicity (ADCC) effect. DS-1055a (FUT8-KO) can effectively eliminate GARP-positive regulatory T cells in the tumor microenvironment and activate effector T cells. DS-1055a (FUT8-KO) has anti-tumor activity and can be used in cancer research (such as colon cancer) .

HY-P991944A

*ZL-1218 (FUT8-KO)*	CCR	Cancer
ZL-1218 (FUT8-KO) is an anti-CCR8 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody. ZL-1218 (FUT8-KO) can be used for the research of solid tumour .

HY-P991481A

*S-531011 (FUT8-KO)*	CCR	Inflammation/Immunology Cancer
S-531011 (FUT8-KO) is an anti-CCR8 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody. S-531011 (FUT8-KO) can be used for the research of cancer immunity .

HY-P991135A

*Enzelkitug (FUT8-KO)* RO-7502175 (FUT8-KO); RG-6411 (FUT8-KO)	CCR	Cancer
Enzelkitug (RO-7502175; RG-6411) (FUT8-KO) is an anti-CCR8 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody. Enzelkitug (FUT8-KO) can be used for the research of various solid tumors and hematological malignancies .

HY-P990755A

*Pamvatamig (FUT8-KO)*	EGFR	Cancer
Pamvatamig (FUT8-KO) is an anti-EGFR/MET monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody.

HY-P991514A

*MIL62 (FUT8-KO)*	CD20	Cancer
MIL62 (FUT8-KO) is a CD20-targeting antibody that prepared by knocking out the fucosyltransferase 8 gene (FUT8) to remove fucose and thereby enhance the ADCC activity of the antibody .

HY-P99014A

*Cusatuzumab (FUT8-KO)*	Transmembrane Glycoprotein	Cancer
Cusatuzumab (FUT8-KO) is an anti-CD70 monoclonal antibody that prepared by knocking out the fucosyltransferase 8 gene (FUT8) to remove fucose and thereby enhance the ADCC activity of the antibody .

HY-P99226A

*Daxdilimab (FUT8-KO)*	Human leukocyte immunoglobulin (Ig)-like receptors (LILR)	Inflammation/Immunology
Daxdilimab (FUT8-KO) is an anti-ILT7 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody.

HY-P991942A

*Lanerkitug (FUT8-KO)* BAY3375968 (FUT8-KO); TPP-23411 (FUT8-KO)	CCR	Cancer
Lanerkitug (FUT8-KO) (BAY3375968 (FUT8-KO)) is an anti-CCR8 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Lanerkitug (HY-P991942) selectively depletes human CCR8+Tregs via antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). Lanerkitug can be used in the research of solid tumors .

HY-RS17190

Fut8 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Fut8 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Fut8 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Fut8 Mouse Pre-designed siRNA Set A Fut8 Mouse Pre-designed siRNA Set A

HY-RS23641

Fut8 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Fut8 Rat Pre-designed siRNA Set A contains three designed siRNAs for Fut8 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Fut8 Rat Pre-designed siRNA Set A Fut8 Rat Pre-designed siRNA Set A

Cat. No.	Product Name	Type